Cyclosporin A is now well established as an eective second-line drug to treat rheumatoid arthritis. In April 1995, the microemulsion-based formulation of cyclosporin (Neoral) was introduced based on its increased bioavailability at`no extra cost'. There may have been concerns that with increased bioavailability of Neoral, some patients might experience increased toxicity, particularly if transferring from Sandimmun to Neoral at the same dose. We describe our experience of 51 patients treated with NeoralÐ39 with rheumatoid arthritis, six with psoriatic arthritis and the remainder with a variety of diseases, including Behc°et's, systemic lupus erythematosus and juvenile chronic arthritis. All patients continued their other medication including non-steroidal anti-in¯ammatory drugs and analgesics. Five continued low dose prednisolone (average 7.5 mg per day) all patients were monitored for safety and ecacy throughout their treatment according to standard protocol. Five patients were enrolled in a study of ecacy and safety where the dose of cyclosporin was reduced to 2.5 mg/kg/day at the time of conversion, i.e. to Neoral 2.5 mg/kg/day; 19 patients were converted dose for dose, cyclosporin A dose range 2.5±4 mg/kg/day converted to Neoral dose range 2.5±4 mg/kg/day and 27 patients started Neoral de novo. We conclude that cyclosporin is a useful disease modifying anti-rheumatic agent, and our experience suggests that the new formulation, Neoral, has a similar safety and ecacy pro®le to the original preparation (Sandimmun). Neoral was relatively easy to manage and we noted a slight reduction in dose when compared to Sandimmun. With dose adjustments over 18 months the mean dose for patients with RA fell from 3.2 to 2.7 mg/kg/day and of the 27 patients starting Neoral de novo only seven required an increased dose above 2.5 mg/kg/day in order to establish ecacy.
OVER the last decade, rheumatologists have used second-line drugs more frequently to treat rheumatoid arthritis (RA), especially in patients with early disease. Cyclosporin obtained a product licence as a second-line drug 3 yr ago, leading to its increasing usage subsequently. Approximately 18 months ago, the makers of cyclosporin introduced a new preparation,`Neoral', which may have caused some concern in those with only limited experience of cyclosporiǹ A'. We therefore describe our experience of the use of cyclosporin in its original preparation, Sandimmun, over the last 7 yr and using the new preparation, Neoral, in patients with rheumatic disease.
We initially treated patients with severe RA who had failed conventional treatment, were unsuitable for second-line drugs, or who needed steroid-sparing agents. Later, we treated patients with early RA using cyclosporin as the ®rst second-line drug and also treated a small number of patients with scleroderma, eosinophilic fasciitis, juvenile chronic arthritis, uveitis, psoriatic arthritis, enteropathic arthritis, BehcË et's disease and mixed connective tissue disease.
The side-eect pro®le in our patients was very similar to other series and has been documented elsewhere [1] . Nephrotoxicity was common, but manageable as long as we adhered to monitoring guidelines.
In April 1995, the microemulsion-based formulation of cyclosporin (Neoral) was introduced based on its increased bioavailability at`no extra cost'. Indeed, it was suggested that there might be a cost reduction if ecacy could be established at lower doses.
PATIENTS AND METHODS
We have treated two groups of patients with Neoral in the last 18 months. Twenty-four patients were converted from Sandimmun to Neoral (®ve as part of a clinical trial) and 27 other patients started Neoral de novo.
Of these 51 patients, 39 had RA, six psoriatic arthritis, one enteropathic arthritis, two BehcË et's disease, one systemic lupus erythematosus and two juvenile chronic arthritis. Their mean age was 54 yr with a mean disease duration of 10.2 yr (range 2 months± 29 yr). All patients continued their other medication, including non-steroidal anti-in¯ammatory drugs (NSAIDs) and analgesics. Five continued low-dose (average 7.5 mg) prednisolone.
Conversion from Sandimmun to Neoral
Because of the possible improvement in bioavailability of Neoral, there were concerns that by transferring patients at the same dose there would be increased toxicity. Careful monitoring was therefore undertaken. This included regular blood tests, incorporating full blood count, erythrocyte sedimentation rate (ESR), urea and electrolytes, creatinine, liver function tests and C-reactive protein (CRP) (see Data Sheet for full recommendations). All patients were weighed at each visit, and had routine urinalysis and blood pressure performed. Creatinine clearances were measured before treatment and where there was signi- ®cant change in renal function during treatment. Five patients, group I(a), were enrolled in a study of ecacy and safety where the dose of cyclosporin was reduced to 2.5 mg/kg/day at the time of conversion, i.e. to Neoral 2.5 mg/kg/day; this reduction was made regardless of their previous dose of Sandimmun. The other 19 patients, group I(b), were converted dose for dose, i.e. Sandimmun ranging from 2.5 to 4 mg/kg/day to Neoral ranging from 2.5 to 4 mg/kg/day.
Starting Neoral de novo
Of these 27 patients, seven had a disease duration of <2 yr and Neoral was given as the ®rst`secondline agent'Ðthree also received methotrexate in combination with cyclosporin. These patients received 2.5 mg/kg/day of Neoral and were monitored according to the guidelines, with adjustment in dose based on clinical ecacy and renal function. Monitoring was undertaken at regular intervals (see above).
Disease activity was monitored using the Ritchie articular index, a 10 cm visual analogue scale for pain and the Health Assessment Questionnaire.
RESULTS

Group I(a)Ð®ve patients
The dose range of Sandimmun prior to conversion was 2.8±3.9 mg/kg/day. All ®ve patients were reduced to 2.5 mg/kg/day of Neoral (Table I) . This resulted in a signi®cant¯are in arthritis in two patients and a minor¯are in two others, i.e. ecacy was only maintained in one patient. Interestingly, she lost weight during the period of conversion and when the dose was recalculated at 3 months, she required a dose reduction of 25 mg/day according to her weight, with no change in ecacy or renal function.
Group I(b)Ð19 patients
Direct conversion dose for dose from Sandimmun to Neoral resulted in no problems in terms of ecacy or in laboratory assessments of disease activity. A few patients did have a rise in serum creatinine, but this was only seen in patients in whom the dose was >2.8 mg/kg/day, who also had RA and after a period of H3 months. With dose adjustments, the mean dose for RA had fallen from 3.2 to 2.7 mg/kg/day after a year (Table II) .
Group IIÐ27 patients
Twenty-seven patients started Neoral de novo: 22 with RA and ®ve with psoriatic arthritis (Table III) . The mean age was 54 yr, with a mean disease duration of 11 yr (range 1±29 yr). Neoral was started at a dose of 2.5 mg/kg/day and only seven of the 27 patients required an increase to establish ecacy. The dose increase was very modest at only 25 mg/day.
Three patients had Neoral as their ®rst`secondline' treatment, but they all appeared to respond more quickly and more eectively than patients with more established disease.
Side-eects in all three studies were similar to our experience with Sandimmun. For example, two patients developed mild hypertension which was easily controlled. Both patients were in their sixties and also on prednisolone. There was no increased incidence of hypertension when Neoral was introduced in place of Sandimmun.
Two patients who had been on nifedipine prior to commencing Neoral developed facial¯ushing when cyclosporin was started. There was no obvious relationship between treatment with drugs such as nifedipine and an increase in cyclosporin toxicity however.
DISCUSSION
We have now treated 51 patients with the Neoral formulation of cyclosporin. Our experience suggests that Neoral has a similar safety and ecacy pro®le to Sandimmun, the conventional formulation. We found Neoral relatively easy to manage in a similar way to Sandimmun and noted a slight reduction in dose when compared to Sandimmun. It is important to recognize that this is a descriptive paper and the numbers of patients treated in each group were small. Despite this, it represents a considerable clinical experience compared with other rheumatology groups in the UK at this moment in time.
The side-eect pro®le with Neoral appeared to be similar to that of Sandimmun and we therefore consider monitoring to be important, particularly regarding renal toxicity and hypertension. However, as long as guidelines were followed, we found no major problems.
In our overall experience with cyclosporin, we have encountered diculties when large alterations are made to the dose, which are advised in the protocol for cyclosporin use. We have lost ecacy by reducing the dose by 50 mg, and run into problems with toxicity when sudden large increases are made to the dose. The main problem with the rapid increase in dose was deterioration in renal function with, on some occasions, increased serum creatinine in excess of 50% above baseline. This was particularly common in patients on >3.5 mg/kg/day of Sandimmun. A rapid dose reduction was often required to reduce the serum creatinine, resulting in loss of ecacy. Such changes also made it dicult to re-establish ecacy even with more gradual changes. As a consequence of this experience, we now always alter the dose of cyclosporin slowly to achieve the lowest possible dose required for clinical ecacy.
The key points from our experience with Neoral are as follows: (1) Follow monitoring guidelines closely.
(2) Dose changes should be infrequent, and no greater than 25 mg/day. (3) Patients should start at a low dose. Patients starting at 2.5 mg/kg/day may require one increase in dose after 6±8 weeks, which is usually sucient. Occasionally, patients respond to a dose of <2.5 mg/kg/day. Particular caution is required in patients who are losing weight, in whom dose adjustments have to be made according to the change in weight. We, like others, have used cyclosporin in combination with other second-line agents. Combinations include the addition of methotrexate and prednisolone; azathioprine, sulphasalazine and prednisolone for a patient with enteropathic arthritis; methotrexate, thalidomide and prednisolone in two patients with BehcË et's disease. We have not found any problems in terms of drug interactions and any side-eects have been similar to those with each individual drug.
Based on the experience of Tugwell et al. [2] , we are using this combination therapy in some patients with early active RA who have features suggesting a poor prognosis [3, 4] . In patients with early disease, especially relatively young patients, we ®nd fewer problems with renal function. The reason for using cyclosporin early in disease is its potential to delay destructive changes, including erosions, as noted by the GRISAR data [5] . Our main problems with cyclosporin have been in older patients with longstanding RA who have evidence of impaired renal function pre-treatment. It is sometimes dicult to distinguish the deterioration in renal function due to cyclosporin from the eects of other drugs, including NSAIDs [6] .
Cyclosporin is a useful disease-modifying antirheumatic agent. Its activity and ecacy have been well established in a number of other studies. Our experience suggests that the new formulation, Neoral, is an eective way of using cyclosporin. The dose we used was slightly lower than that of Sandimmun, suggesting that it may have increased bioavailability. 
